May 5, 2025 07:27 PM EDT

Vertex touts promising first few months of launch for non-opioid pain drug Journavx

Lei Lei Wu

News Reporter

Vertex said it’s gathering momentum with its new product launches, building out new franchises with its sickle cell therapy Casgevy, another cystic fibrosis drug in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vertex touts promising first few months of launch for non-opioid pain drug Journavx

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Early bits of in vivo CAR-T human data emerge from biotech trials in China

Bristol Myers to lay off over 500 workers in New Jersey

Recursion cuts nearly half of its pipeline, including its most advanced program

PTC's Huntington’s study succeeds, but accelerated approval uncertain

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Ver­tex touts promis­ing first few months of launch for non-opi­oid pain drug Jour­navx

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

Bris­tol My­ers to lay off over 500 work­ers in New Jer­sey

Re­cur­sion cuts near­ly half of its pipeline, in­clud­ing its most ad­vanced pro­gram

PTC's Hunt­ing­ton’s study suc­ceeds, but ac­cel­er­at­ed ap­proval un­cer­tain

J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

Vertex touts promising first few months of launch for non-opioid pain drug Journavx

Early bits of in vivo CAR-T human data emerge from biotech trials in China

Bristol Myers to lay off over 500 workers in New Jersey

Recursion cuts nearly half of its pipeline, including its most advanced program

PTC's Huntington’s study succeeds, but accelerated approval uncertain

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges